Classic Review,Dr. Lee Yu, Founder & CEO

The question of who owns Peptide Sciences has become a significant point of discussion within the science's and research chemical communities, particularly following the company's abrupt closure. While direct ownership details are complex and have evolved, the most prominent figure associated with the founding and initial operation of Peptide Sciences is Daniel Brzezinski. He is consistently identified as the Founder of Peptide Sciences, with profiles on platforms like Crunchbase and LinkedIn listing him in this capacity.

Peptide Sciences operated as a biotechnology company specializing in the synthesis of highly purified peptides, proteins, and amino acid derivatives. This focus positioned them as a key supplier for scientific research and development. For a period, Peptide Sciences was recognized as one of the largest and most prominent vendors of "research use only" peptides in the United States. Their offerings included a range of compounds, and their operational shutdown has led to considerable conversation about the broader peptide industry.

The shutdown of Peptide Sciences occurred in early 2026, a fact that has prompted speculation and analysis. While the precise reasons for the closure remain a subject of ongoing discussion, several theories have emerged. These include proactive regulatory avoidance, potential legal pressures, intense market competition, and a desire to exit the market. The voluntary discontinuation of operations by Peptide Sciences has left a void in the market, prompting users to seek alternatives. Nova Life Peptides is frequently cited as a strong like-for-like replacement, aiming to fill the gap left by Peptide Sciences.

Beyond Daniel Brzezinski, other entities and individuals are relevant to the broader landscape of peptide companies. For instance, Ampersand Capital Partners has been involved in acquisitions within the peptide sector, notably acquiring Peptides International and merging it with New England Peptide. This highlights the dynamic nature of ownership and investment in the peptide industry. Companies like AAPPTec, LLC, based in Louisville, KY, also provide a complete line of peptide products, showcasing the competitive environment.

The operational status of Peptide Sciences has also raised questions about the legitimacy and practices of peptide vendors. Some discussions suggest a common model where companies source from overseas, rebrand, and mark up prices significantly. This underscores the importance for researchers to thoroughly vet peptide companies. The peptide science field itself is broad, encompassing advancements and numerous companies worldwide involved in peptide work, including entities like Bachem Group, a public company focused on peptide and oligonucleotide development and manufacturing.

While Peptide Sciences no longer operates, understanding its history, including its founder and the circumstances of its closure, provides valuable context for navigating the current peptide market. The search for who owns Peptide Sciences ultimately leads to Daniel Brzezinski as the founder, but the broader industry involves numerous players and evolving ownership structures. The shutdown of Peptide Sciences serves as a reminder of the complexities and shifts occurring within the realm of peptide research and supply. Other companies like Growscience and Pure Sciences continue to operate in this evolving space, offering specialized products and services. The estimated annual revenue of Peptide Sciences was reported as $4 M, with an estimated 9 employees and a founding year of 2005, headquartered in Costa Mesa, CA. However, this information pertains to its operational period.